Relapse of COVID-19-associated mucormycosis in patients receiving posaconazole as maintenance treatment.

Autor:	Salehi M; Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Khodavaisy S; Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran ., Kamali Sarvestani H; Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran ., Sobati A; Department of Nursing and Midwifery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran ., Pakdel F; Department of Oculo-Facial Plastic Surgery, Department of Ophthalmology, Farabi Hospital, Tehran University of Medical Sciences, Tehran, Iran., Samiee Fard E; Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Darvishi M; Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran ., Shavandi M; Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran., Mussini C; Department of Infectious Diseases and Tropical Medicine, University of Modena and Reggio Emilia, Modena, Italy., Rafat Z; Department of Medical Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran., Ahmadikia K; Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran., Tabari A; Otorhinolaryngology Research Center, Imam Khomeini Hospital complex, Tehran University of Medical Sciences, Tehran, Iran.
Jazyk:	angličtina
Zdroj:	Journal of infection in developing countries [J Infect Dev Ctries] 2024 Sep 30; Vol. 18 (9.1), pp. S163-S169. Date of Electronic Publication: 2024 Sep 30.
DOI:	10.3855/jidc.19645
Abstrakt:	Introduction: Coronavirus disease 2019 (COVID-19) has been associated with secondary fungal infections such as mucormycosis. We investigated the relapse rate of mucormycosis and its risk factors. Methodology: A prospective study was conducted on COVID-19-associated mucormycosis (CAM) patients discharged from Imam Khomeini Hospital Complex, Tehran, Iran, from July 2021 to February 2022. Patients who received posaconazole as a step-down therapy were included and examined monthly for six months. A relapsing mucormycosis case was defined as a patient with new clinical or radiological symptoms, confirmed by observing aseptate hyphae in the histopathological examination or tissue culture. The characteristics of patients with and without relapse were analyzed and compared. Results: Seventy-seven patients completed the six-month follow-up after discharge. Most patients were male (n = 46, 59.8%), with a mean age of 53.1 years (median 19-84). The most common underlying diseases were diabetes (52/77, 67.5%), hypertension (33/77, 42.8%), and cancer/chemotherapy (25/77, 32.4%). Seven patients (7/77, 9%) were reported as relapsing cases. There was no difference in demographic features and underlying diseases between the groups. A significant difference was seen in the mean duration of posaconazole consumption between patients with and without relapse (24 ± 4.4 days vs. 49.4 ± 4.3 days, respectively, p = 0.015). The primary orbital involvement was also significantly associated with relapse (p = 0.04). Conclusions: Our findings showed a significant relapse of CAM (9%). A longer duration of posaconazole consumption and completion of treatment for initial orbital involvement in CAM patients are recommended for better patient management and prevention of relapse. Competing Interests: No Conflict of Interest is declared (Copyright (c) 2024 Mohammadreza Salehi, Sadegh Khodavaisy, Hasti Kamali Sarvestani, Abolfazl Sobati, Farzad Pakdel, Elahe Samiee Fard, Marzieh Darvishi, Mehrdad Shavandi, Cristina Mussini, Zahra Rafat, Kazem Ahmadikia, Azin Tabari.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF